GlassScriptPhysician profile
Patrick Michael Horne
NPI 1487827960
$50,794.87
in general payments reported to CMS, 2019-2025
14 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,637 · 2022: $2,500 · 2023: $4,028 · 2024: $13K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $5,038 · Food and Beverage: $4,166 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,165 · Honoraria: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,098.75 |
| Travel and Lodging | $5,038.27 |
| Food and Beverage | $4,165.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,165.00 |
| Honoraria | $2,190.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $10,660.66 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $8,828.54 | 2021-2025 | |
| Glaxosmithkline, LLC. | $8,075.00 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,035.29 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,603.82 | 2024-2025 | |
| Gilead Sciences, INC. | $3,799.11 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $3,011.21 | 2021-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $2,991.47 | 2024-2025 | Iqirvo, Bylvay |
| Mirum Pharmaceuticals, INC. | $1,551.81 | 2025 | Livmarli |
| Novo Nordisk INC | $945.21 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $109.56 | 2024 | |
| Alexion Pharmaceuticals, INC. | $79.80 | 2022 | |
| Genzyme Corporation | $73.78 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $29.61 | 2024 | Utaswako Afp-L3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Horne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.